SUVN-I6107
/ Suven Life Sci
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
January 09, 2025
Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders
(Yahoo Finance)
- "India-based Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders."
Trial status • CNS Disorders
January 09, 2025
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Suven Life Sciences Limited | Not yet recruiting ➔ Recruiting
Enrollment open
November 26, 2024
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: Suven Life Sciences Limited
New P1 trial
August 30, 2024
Suven Life Sciences announces FDA acceptance of investigational new drug
(Indian Pharma Post)
- "Suven Life Sciences...has announced the acceptance of its Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) and grant of 'Study may proceed Letter' to evaluate SUVN-I6107 in a first-in-human phase-1 clinical trial...Preclinical evidence has shown that treatment with SUVN-I6107 results in precognitive properties in diverse animal models. Additionally, SUVN-I6107 was devoid of cholinergic side effects at doses effective in animal models...We look forward to dosing the first subject with SUVN-I6107 during the H2-2024 with an expected data readout in the H1-2025...The primary endpoint will assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs."
IND • New P1 trial • CNS Disorders • Dementia
July 07, 2023
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders
(AAIC 2023)
- "It also attenuated scopolamine-induced memory deficit in the object recognition as well as contextual fear conditioning task. SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects"
Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • APP
July 07, 2023
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders
(AAIC 2023)
- "It also attenuated scopolamine-induced memory deficit in the object recognition as well as contextual fear conditioning task. SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects"
Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • APP
July 07, 2023
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders
(AAIC 2023)
- "It also attenuated scopolamine-induced memory deficit in the object recognition as well as contextual fear conditioning task. SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects"
Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • APP
July 07, 2023
SUVN-I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders
(AAIC 2023)
- "It also attenuated scopolamine-induced memory deficit in the object recognition as well as contextual fear conditioning task. SUVN-I6107 enhanced cerebral blood flow, potentiated the effects of donepezil and promoted non-amyloidogenic amyloid precursor protein processing in rats... SUVN-I6107, a novel, potent and selective M1-PAM demonstrated efficacy in animal models and devoid of cholinergic side effects"
Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • APP
1 to 8
Of
8
Go to page
1